Literature DB >> 3159336

Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.

F M Gordin, C J Hackbarth, K G Scott, M A Sande.   

Abstract

Pefloxacin and ciprofloxacin are two new quinoline carboxylic acid derivatives that have activity in vitro against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa. Using a well-standardized model of Pseudomonas pneumonia in neutropenic guinea pigs, we tested the efficacy in vivo of these new agents. Both were highly effective in increasing survival and decreasing bacterial counts in the lungs of surviving animals. Pefloxacin and ciprofloxacin were significantly better (P less than 0.05) than aminoglycosides or beta-lactams tested in prior studies with this model, and they were as effective as combination therapy with aminoglycosides and beta-lactams. Resistance to either ciprofloxacin or pefloxacin did not emerge during the study period. Further studies with these drugs in the therapy of Pseudomonas sp. infections are warranted.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159336      PMCID: PMC180073          DOI: 10.1128/AAC.27.4.452

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Aerobic gram-negative bacillary pneumonias.

Authors:  A K Pierce; J P Sanford
Journal:  Am Rev Respir Dis       Date:  1974-11

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].

Authors:  A Thabaut; J L Durosoir
Journal:  Pathol Biol (Paris)       Date:  1982-06

4.  [Structure-activity relationships in the quinolone group: antibacterial activity of two new compounds (author's transl)].

Authors:  M Thibault; B Koumaré; C J Soussy; J Duval
Journal:  Ann Microbiol (Paris)       Date:  1981 May-Jun

5.  Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs.

Authors:  M G Rusnak; T A Drake; C J Hackbarth; M A Sande
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

6.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

7.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors:  D L Van Caekenberghe; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

9.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

10.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

View more
  18 in total

Review 1.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

2.  Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; M T ten Kate; L Guo; P Working; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.

Authors:  M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

4.  Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

Review 5.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice.

Authors:  K Oishi; F Sonoda; A Iwagaki; S Kobayashi; T Nagatake; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 7.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

8.  Comparative efficacy of ciprofloxacin, ceftazidime and gentamicin, given alone or in combination, in a model of experimental septicemia due to Klebsiella pneumoniae in neutropenic mice.

Authors:  M Trautmann; O Brückner; R Marre; H Hahn
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 9.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 10.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.